The Administrative Core A, led by the Project Director, Dr. Richard Wyatt, will provide general management and administrative support for all Projects 1-4 and Core B under the HIVRAD POl. Additionally, this Core will coordinate an administrative plan to maintain clear lines of communication with investigators and collaborators within the bounds ofthe HIVRAD. Furthermore, communication with advisory board members and interactions with external researchers with interests in the HlV-1 Env-based vaccines and the analysis of B cell responses elicited of selected HIV-1 envelope glycoproteins candidates will be facilitated.
The first Aim will be to establish a project management plan designed by the Program Director with the goal to ensure the success ofthe HIVRAD through the several steps including a) continuous monitoring ofthe scientific progress of each component ofthe program, b) encouraging and leading internal communications among the individual investigators at each institution c) informing the appropriate officials at NIH of progress via teleconferences or email summaries d) provide fiscal review to ensure that all financial resources are appropriately utilized and e) initiating collaborations with investigators not currently part of this program.
The second Aim of this Core will be to form of a Scientific Advisory Board (SAB) and schedule annual meetings to evaluate progress and success of this HIVRAD program project.

Public Health Relevance

This Core will oversee the coordination of all the Projects and Cores designed to elicit broadly neutralizing antibodies to the human pathogen HIV-1 toward the goal of a broadly effective vaccine. Thereby, this Core will have a direct impact on the improvement of human public health.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
La Jolla
United States
Zip Code
Khan, Salar N; Sok, Devin; Tran, Karen et al. (2018) Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry. J Virol 92:
Sarkar, Anita; Bale, Shridhar; Behrens, Anna-Janina et al. (2018) Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer. Nat Commun 9:1956
Yang, Lifei; Sharma, Shailendra Kumar; Cottrell, Christopher et al. (2018) Structure-Guided Redesign Improves NFL HIV Env Trimer Integrity and Identifies an Inter-Protomer Disulfide Permitting Post-Expression Cleavage. Front Immunol 9:1631
Bale, Shridhar; Martiné, Alexandra; Wilson, Richard et al. (2018) Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies. Front Immunol 9:1116
Singh, Rajendra; Stoneham, Charlotte; Lim, Christopher et al. (2018) Phosphoserine acidic cluster motifs bind distinct basic regions on the ? subunits of clathrin adaptor protein complexes. J Biol Chem 293:15678-15690
Cale, Evan M; Gorman, Jason; Radakovich, Nathan A et al. (2017) Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. Immunity 46:777-791.e10
Karlsson Hedestam, Gunilla B; Guenaga, Javier; Corcoran, Martin et al. (2017) Evolution of B cell analysis and Env trimer redesign. Immunol Rev 275:183-202
Dubrovskaya, Viktoriya; Guenaga, Javier; de Val, Natalia et al. (2017) Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response. PLoS Pathog 13:e1006614
Voss, James E; Andrabi, Raiees; McCoy, Laura E et al. (2017) Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. Cell Rep 21:222-235
Kwong, Peter D; Chuang, Gwo-Yu; DeKosky, Brandon J et al. (2017) Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1. Immunol Rev 275:108-128

Showing the most recent 10 out of 44 publications